Background Adding docetaxel to androgen deprivation therapy (ADT) improves survival in
patients with metastatic, hormone-sensitive prostate cancer, but uncertainty remains about …

The advent of more effective treatment combinations for metastatic hormone-sensitive
prostate cancer (mHSPC) has been built on successes in therapy development for …

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions
regarding the workup of patients with prostate cancer, risk stratification and management of …

Simple Summary De novo metastatic hormone-sensitive prostate cancer usually has a
dismal prognosis, which has slightly improved in recent years thanks to the introduction of …

Simple Summary Prostate cancer is the second most frequently occurring cancer in men,
and patients with advanced prostate cancer have poor long-term survival. Chemotherapy is …

Simple Summary Prostate cancer is the most common non-cutaneous malignancy among
men in the United States. Bone metastases and health are crucial issues in prostate cancer …

Background Whether disease burden in patients with metastatic castration-sensitive prostate
cancer (mCSPC) predicts treatment outcomes is unknown. We assessed apalutamide …

Importance Cardiovascular (CV) events remain a substantial cause of mortality among men
with advanced and metastatic prostate cancer (PCa). The introduction of novel androgen …

PURPOSE Despite major increases in the longevity of men with metastatic hormone-
sensitive prostate cancer (mHSPC), most men still die of prostate cancer. Phase III trials …

Abstract Zinc sulfide/graphitic Carbon Nitride binary nanosheets were synthesized by using
a novel sonochemical pathway with high electrocatalytic ability. The as-obtained samples …